Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Advanced Solid Tumor 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Appointments and Schedules × Clear all
NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Juno Therapeutics, a Subsidiary of Celgene

Phase 1 Completed
387 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡